The blood–brain barrier protects neural tissue by tightly regulating which substances can leave the bloodstream and enter the brain. While this defense is essential for preventing toxins and pathogens from reaching delicate neurons, it also blocks many potentially valuable drugs, including proteins, nucleic acids and some small-molecule therapies. As a result, treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, brain tumors, epilepsy and stroke may require high systemic doses, invasive administration or delivery methods that remain difficult to scale.

Intranasal administration has attracted intense interest because the upper nasal cavity provides anatomical connections to the brain through the olfactory and trigeminal nerve pathways. Drugs deposited near the olfactory epithelium may move along or around these pathways, potentially reaching regions of the central nervous system without first circulating throughout the body. This concept, often described as nose-to-brain delivery, could reduce systemic exposure and allow therapeutics to act more directly at their intended site. Yet the nasal route is not automatically efficient: mucus, enzymatic degradation, rapid clearance and limited absorptive surface area can all reduce the amount of medicine that reaches neural tissue.

The review focuses on autonomous systems engineered to respond to their biological surroundings rather than simply releasing a drug at a predetermined rate. These platforms may use nanoscale or microscale carriers that alter their behavior when they encounter changes in pH, temperature, enzymes, ionic strength or other features of the nasal environment. Some are designed to adhere temporarily to the nasal mucosa, extending residence time despite the constant movement of mucus toward the throat. Others can change their structure, swell, dissolve or release their cargo in response to local signals, creating a more controlled delivery profile.

Nanoparticles are central to many of these approaches. Lipid-based particles, polymeric nanoparticles, nanogels and other engineered carriers can protect fragile payloads from degradation and improve their interaction with nasal tissues. Surface chemistry is particularly important. By adding mucoadhesive components, researchers can help particles remain in contact with the epithelium; by incorporating mucus-penetrating coatings, they may enable carriers to move through the mucus layer and approach the underlying cells. The challenge is to balance these opposing properties, because excessive adhesion can trap a carrier in mucus while insufficient adhesion can lead to rapid removal.

Autonomous delivery systems may also be engineered to cross cellular barriers or release medicines only after reaching a particular biological compartment. For example, a carrier could protect a protein or messenger RNA during administration, promote uptake by nasal epithelial cells and then release its cargo inside the cell. Other designs aim to transport drugs along neuronal pathways or encourage passage through tissues surrounding the olfactory bulb. These strategies are especially relevant for biologics, whose large size and chemical instability make them difficult to deliver by traditional routes.

The technology could eventually support therapies that are difficult to administer using standard nasal sprays. Small-volume devices, precision nozzles and electronically controlled applicators may improve deposition in the upper nasal cavity, while smart formulations could respond to the local environment after administration. Some future systems may combine sensing, movement and drug release in a single platform, allowing them to adapt to patient-specific conditions such as mucus composition, inflammation or variations in nasal anatomy. Such “autonomous” behavior remains largely a research goal, but it reflects a broader shift toward delivery systems that actively manage their own interaction with the body.

Despite the promise, the review emphasizes that nose-to-brain delivery is accompanied by substantial biological and engineering challenges. The nasal cavity varies considerably between individuals, and factors including age, congestion, allergies, disease, breathing patterns and prior surgery can alter deposition and absorption. Much of an intranasal dose may still be swallowed or enter the bloodstream rather than reaching the brain. Researchers must also establish whether a drug detected in brain tissue arrived through a genuine neural pathway or simply crossed the blood–brain barrier after systemic absorption. Reliable imaging, pharmacokinetic measurements and standardized animal and human models will be essential for resolving this question.

Safety is another major consideration. Repeated exposure to nanoparticles, polymers or penetration-enhancing chemicals could irritate or damage the nasal epithelium, disrupt the sense of smell or trigger immune responses. Materials must be carefully evaluated for toxicity, biodegradability and long-term accumulation. Manufacturing presents an additional hurdle: complex multifunctional carriers must be produced consistently, sterilized without losing performance and packaged in devices that deliver accurate doses. Before autonomous intranasal systems can become routine clinical tools, they will require rigorous testing in humans to demonstrate reproducible brain targeting, meaningful therapeutic benefit and acceptable safety.

The review presents intranasal delivery as more than a convenient alternative to injections. By combining biomaterials science, nanotechnology, neurobiology and device engineering, autonomous systems could create a new generation of brain-targeted medicines capable of protecting sensitive cargo, overcoming mucosal barriers and releasing therapy in response to local conditions. The field is still moving from sophisticated laboratory prototypes toward clinically validated products, but its central ambition is clear: to make treatment of the brain less invasive, more precise and more adaptable to the complex biology of each patient.

Subject of Research: Autonomous intranasal delivery systems for transporting therapeutics to the central nervous system

Article Title: Autonomous intranasal delivery systems for central nervous system therapeutics

Article References: Shen, H., Srivastava, S.K., Aggarwal, N. et al. Autonomous intranasal delivery systems for central nervous system therapeutics. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01781-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01781-5

Keywords: intranasal drug delivery, nose-to-brain delivery, central nervous system therapeutics, blood–brain barrier, nanomedicine, autonomous delivery systems, nanoparticles, neurotherapeutics

The blood-brain barrier has long been a double-edged sword in neuroscience and drug delivery. While it protects the brain from potentially harmful substances, it simultaneously restricts most therapeutics from crossing into the brain parenchyma, particularly large molecules and advanced nanostructures. The innovation detailed in this study involves circumventing the BBB entirely by utilizing the intranasal route, allowing direct access to the central nervous system through the olfactory and trigeminal nerves. This method significantly reduces systemic exposure and leverages the natural anatomical pathways to facilitate rapid brain delivery.

Central to this breakthrough is the design of a nanolamellar structure engineered to sequentially release payloads directly into mitochondria—the powerhouses of the cell and pivotal players in ischemic stroke pathology. Mitochondrial dysfunction is a hallmark of ischemic injury, leading to energy failure and cell death. Targeting mitochondria presents a highly strategic therapeutic avenue, as the restoration of mitochondrial function can halt or reverse the cascade of neuronal damage initiated by stroke.

The nanolamellar system is bioengineered with exquisite precision, incorporating components that navigate the biological milieu of the brain’s extracellular matrix while preserving stability during passage from the nasal epithelium. This system is layered at the nanoscale, with each layer programmed to release therapeutic agents sequentially, facilitating a timed release that mirrors the pathophysiological progression of ischemic injury. This ensures drugs are delivered at the optimal timeframes for maximum neuroprotection and tissue repair.

Intranasal administration, the route chosen for this delivery system, circumvents enzymatic degradation and hepatic first-pass metabolism, common pitfalls in systemic drug delivery. It enables high bioavailability of therapeutic agents directly to the brain. The olfactory nerve pathways provide a direct conduit for nanolamellar particles to reach various brain regions, including the ischemic penumbra— the zone critical for neuroprotection and the potential rescue of neurons.

Technically, the nanolamellar system is fabricated through advanced bioengineering techniques combining lipid-based nanotechnology with mitochondrial targeting ligands. The researchers employed a modular design that integrates hydrophobic and hydrophilic regions, facilitating the encapsulation of diverse therapeutic molecules ranging from antioxidant enzymes to small molecular drugs. The surface of these lamellar structures is functionalized with mitochondria-penetrating peptides, improving mitochondrial membrane permeabilization and subsequent drug delivery within the targeted organelles.

Upon reaching the mitochondria, the controlled release mechanism triggers the sequential liberation of agents aimed at reducing oxidative stress, restoring bioenergetics, and preventing apoptotic signaling cascades. This multi-pronged approach is critical for halting the extensive neuronal death cascade that follows ischemic stroke events. Initial preclinical models demonstrated remarkable reduction in infarct size, improved neurological function, and marked preservation of neuronal morphology compared to conventional treatments.

The implications of this study extend beyond ischemic stroke. The intranasal nanolamellar carrier system presents a versatile platform that could be adapted for a broad spectrum of neurological disorders characterized by mitochondrial dysfunction, including neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. This versatility positions the nanolamellar system as a paradigm shift in central nervous system drug delivery, marrying precision targeting with non-invasive administration.

Crucially, the safety profile of the nanolamellar system was thoroughly evaluated in animal models, revealing excellent biocompatibility and negligible inflammatory response within the nasal mucosa and brain tissues. These findings are vital, given that chronic inflammation can exacerbate neurodegenerative processes and undermine therapeutic efficacy. The bioengineered components are biodegradable, ensuring clearance without accumulation, a common issue with some nanoparticle-based therapies.

The sequential release strategy employed in this nanolamellar system takes inspiration from the complex temporal dynamics of ischemic brain injury. Unlike traditional single-dose therapies, this system administers therapeutics in stages, aligned with distinct phases of ischemic pathology—initial oxidative stress, mitochondrial depolarization, and later apoptotic signaling. This temporal precision offers a sophisticated therapeutic intervention, setting a new benchmark for neuroprotective treatments.

Another exciting facet of this research is the potential for personalized medicine applications. By modifying the nanolamellar layers or the targeting peptides, the system’s payload and release kinetics can be fine-tuned to individual patient profiles, stroke severity, or comorbid conditions. Such customization could revolutionize how stroke therapies are administered, moving away from a one-size-fits-all paradigm toward highly individualized regimens.

The scalability and manufacturability of the nanolamellar system also catch attention. The researchers outlined a reproducible production process amenable to large-scale manufacturing under Good Manufacturing Practice (GMP) standards. This aspect is crucial for translating laboratory success into clinical reality, overcoming common bottlenecks faced by nanomedicine technologies in commercial deployment.

In the broader context of stroke management, timely intervention remains the most critical determinant of patient outcomes. The intranasal nanolamellar delivery system’s rapid brain targeting can potentially extend the therapeutic window, a holy grail in stroke treatment. Early preclinical evidence suggests the system remains effective even when administered hours after ischemic onset, offering hope for patients who present late to medical facilities.

Moreover, this bioengineered system may synergize with current reperfusion therapies, such as thrombolysis or mechanical thrombectomy, by mitigating reperfusion injury—a significant source of additional neural damage following the restoration of blood flow. The ability to support mitochondrial health during this critical phase could enhance recovery and attenuate secondary injury mechanisms.

Looking forward, the translation to human clinical trials will necessitate addressing several challenges, including refining dosing strategies, optimizing delivery devices for consistent intranasal administration, and validating long-term safety and efficacy. Nonetheless, the foundation laid by Yin and colleagues creates a promising pipeline for next-generation stroke therapeutics, marrying cutting-edge bioengineering with translational neuroscience.

This pioneering research underscores the transformative potential of integrating nanotechnology, mitochondrial biology, and innovative delivery routes to tackle previously insurmountable neurological challenges. With ischemic stroke being a leading cause of death and disability worldwide, the global impact of such advances cannot be overstated. This study heralds a new era of targeted neurotherapeutics characterized by precision, efficacy, and patient-centric design.

As the neuroscience community eagerly anticipates further developments, this work serves as a powerful reminder of the critical importance of interdisciplinary approaches in medical innovation. The fusion of molecular engineering, pharmacology, and neuroanatomy demonstrated here exemplifies how fundamental scientific insights translate into therapeutic breakthroughs with the capacity to save millions of lives.

Subject of Research:
Intranasal delivery system to bypass the blood-brain barrier for targeted mitochondrial therapy in ischemic stroke.

Article Title:
Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy.

Article References:
Yin, Y., Li, Z., Shu, W. et al. Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy. Nat Commun (2026). https://doi.org/10.1038/s41467-025-68024-5

Image Credits:
AI Generated